Search

Your search keyword '"Pacor, M.L."' showing total 6 results
Start Over Author "Pacor, M.L."
6 results on '"Pacor, M.L."'

1. Clinical Importance of Eosinophil Count in Nasal Fluid in Patients with Allergic and Non-Allergic Rhinitis

Author

Di Lorenzo, G., primary, Mansueto, P., additional, Pacor, M.L., additional, Martinelli, N., additional, Rizzo, M., additional, Ditta, V., additional, Leto-Barone, M.S., additional, D'Alcamo, A., additional, Politi, D., additional, Pepe, I., additional, Rotolo, G., additional, Di Fede, G., additional, Caruso, C., additional, Rini, G.B., additional, and Corrocher, R., additional

Published
2009
Full Text
View/download PDF

2. Relationship between Specific Serum IGE to Ascaris Lumbricoides and Onset of Respiratory Symptoms in Bangladesh Immigrants

Author

Di Lorenzo, G., primary, Pacor, M.L., additional, Mansueto, P., additional, Esposito-Pellitteri, M., additional, Scichilone, N., additional, Ditta, V., additional, Lo Bianco, C., additional, Leto-Barone, M.S., additional, Di Fede, G., additional, Corrocher, R., additional, Mansueto, S., additional, and Rini, G.B., additional

Published
2006
Full Text
View/download PDF

5. Relationship between Specific Serum IGE to Ascaris Lumbricoidesand Onset of Respiratory Symptoms in Bangladesh Immigrants

Author

Di Lorenzo, G., Pacor, M.L., Mansueto, P., Esposito-Pellitteri, M., Scichilone, N., Ditta, V., Lo Bianco, C., Leto-Barone, M.S., Di Fede, G., Corrocher, R., Mansueto, S., and Rini, G.B.

Abstract

The role of helminths in asthma and/or rhinitis and in allergic sensitization is still unclear. We assessed the relationship between Ascaris-specific IgE, respiratory symptoms and allergic sensitization in Bangladesh immigrants. 246 individuals were examined from 1996 to 2001. Serum total IgE, AscarisIgE, specific IgE to inhalant allergens, skin prick tests (SPT) and parasitological evaluation of the stool were performed. Total serum IgE were significantly higher in Ascaris-IgE positive (> 0.35 kU/L) individuals (806.5 [409.0–1436.0] kU/L vs. 207.0 [127.0–332.5] kU/L; P< 0.0001) and in subjects with respiratory symptoms (413.0 [239.0–1096.0] kU/L vs. 259.5 [147.0–387.0] kU/L), (P< 0.0001), but not in SPT positive subjects (413.0 [179.0–894.0] kU/L vs. 404.6 [305.0–1201.0] kU/L (P= 0.5). Ascaris-specific IgE were detected in 48 subjects with respiratory symptoms (40.0%) and in 46 subjects without respiratory symptoms (36.5%) (P= 0.5). The SPT positivity was similar between Ascaris-IgE seropositive (38.2%) and Ascaris-IgE seronegative (38.1%) subjects (P= 0.9). Total IgE and length of stay in Italy correlated with SPT positivity (OR 5.6 [CI 95% 1.5–19.8], P= 0.007, and OR 1.5 [CI 95% 1.3–1.7], P< 0.0001), and with respiratory symptoms (OR 13.7 [CI 95% 3.0–62.4], P= 0.0007, and OR 2.4 [CI 95% 1.9–3.0], P< 0.0001). Ascaris-IgE were negatively associated with SPT positivity (OR 0.3 [CI 95% 0.1–0.8], P= 0.02) and with respiratory symptoms (OR 0.1 [CI 95% 0.04–0.7], P= 0.01). Our findings favour the role of environmental factors in the development of respiratory symptoms in immigrants, irrespective of Ascaris-IgE.

Published
2006
Full Text
View/download PDF

6. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs

Author

Pacor, M., Di Lorenzo, G., Biasi, D., Barbagallo, M., Corrocher, R., Pacor, M.L., Di Lorenzo, G., Biasi, D., Barbagallo, M., and Corrocher, R.

Subjects
COX-l, ASA, Urticaria, Angioedema, COX, COX-2 inhibitors, NSAID, Rofecoxib, Immunology, COX-2 inhibitor
Abstract

Background: Adverse reactions to non-steroidal anti-inflammatory drugs (NSAID)s are frequent, and the need to identify a safe alternative drug is a common problem in clinical practice. Objective: To assess the tolerability ofrofecoxib, a drug that specifically inhibits COX-2, in a group of NSAID-sensitive patients. Methods: One-hundred and four subjects (29 males and 75 females, mean age 35.6 ± 14.1) were enrolled. All subjects had experienced one or more episode characterized by cutaneous symptoms (erythema, and/or urticaria angioedema) following the assumption of NSAIDs; 92 subjects experienced reactions to only one NSAID (single intolerance: SI) and 12 subjects had reactions to multiple NSAIDs (multiple intolerance: MI). Rofecoxib was challenged at the following dosages: 1/4 of 25 mg (6.25mg), 1/4 of 25mg, and 1/2 of 25mg (12.5mg), at intervals of 1 h if no symptoms had developed with the previous administration, in order to reach a cumulative dose of 25mg. All subjects underwent two double-blind, placebo-controlled challenges in two consecutive days. Results: No reactions against placebo were observed. Similarly, no reactions were observed in all subjects both after the first and after the second challenge to rofecoxib. Conclusions: The present study demonstrated that rofecoxib does not have cross-reactivity to NSAIDs. Rofecoxib is a safe alternative in subjects with previous adverse cutaneous reaction to NSAIDs.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results